Novavax is a 'super volatile stock,' strategist explains
Novavax (NVAX) recently reported its second quarter results, missing estimates on revenue and adjusted earnings while slashing its full-year outlook for revenue. Despite this, Novavax's stock edges hi...
4 days ago - Yahoo Finance
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
On Thursday, Novavax Inc NVAX reported second-quarter 2024 sales of $415 million, compared to$424 milliona year, missing the consensus of $458.6 million.
4 days ago - Benzinga
Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with theU.S. FDA and EMA for authorization of updated 2024-2025 formula COVID...
4 days ago - PRNewsWire
Novavax quarterly revenue misses estimate on weak COVID vaccine sales
Novavax reported second-quarter revenue that was below analysts' estimates on Thursday due to lower-than-expected sales of its COVID-19 vaccine.
5 days ago - Reuters
Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024
GAITHERSBURG, Md. , Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second ...
11 days ago - PRNewsWire
Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 GAITHERSBURG, Md. , June 24, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company ...
7 weeks ago - PRNewsWire
Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U...
2 months ago - PRNewsWire
Novavax stock rises on COVID vaccine delivery projections
Shares of Novavax (NVAX) are surging after the company announced it will meet delivery expectations for the fall COVID vaccine push. All COVID vaccines will use the JN.1 strain, part of the Omicron su...
2 months ago - Yahoo Finance
My Novavax stock price forecast was correct: what next now?
Novavax (NASDAQ: NVAX) stock price has gone parabolic this year, making it one of the best-performing companies in New York. It has soared by over 335% in 2024 and by almost 500% from its lowest level...
2 months ago - Invezz
FDA advisers urge targeting JN.1 strain in fall's COVID vaccines
WASHINGTON — Government advisers Wednesday said it's time to update the recipe for the COVID-19 vaccines Americans will receive in the fall — targeting a version of the ever-evolving coronavirus calle...
Other symbols: MRNAPFE
2 months ago - Market Watch
Novavax to Participate in 2024 Jefferies Global Healthcare Conference
GAITHERSBURG, Md. , May 30, 2024 /PRNewswire/ --Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the...
2 months ago - PRNewsWire
Novavax awaits FDA decision on whether its next COVID shot can be offered in US
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started manufacturing that targets a variant that was dominant earlier this ...
2 months ago - Reuters
Shah Capital ends campaign against Novavax board after Sanofi deal
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's board, after the COVID-19 vaccine maker struck a licensing deal with Sanof...
Other symbols: SNY
3 months ago - Reuters
Up 3x In A Week Will Novavax Stock Continue To See Higher Levels?
The stock price of Novavax (NASDAQ: NVAX), a Covid-19 vaccine developer, trades at $13 per share, about 96% below its peak level of $320 seen in February 2021. NVAX stock was trading at around $51 in ...
3 months ago - Forbes
Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The settlem...
3 months ago - Accesswire
Novavax to Participate in BofA Securities 2024 Health Care Conference
GAITHERSBURG, Md. , May 13, 2024 /PRNewswire/ --Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the...
3 months ago - PRNewsWire
Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
Novavax said the deal with Sanofi allows it to remove its "going concern" warning, which it first issued last year due to doubts about staying afloat.
Other symbols: SNY
3 months ago - CNBC
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal
Novavax shares soared after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Madison Muller reports on Bloomberg Televi...
Other symbols: SNY
3 months ago - Bloomberg Markets and Finance
Novavax (NVAX) Deal with Sanofi to Co-Commercialize Covid Vaccine
Novavax (NVAX) signed a deal with drugmaker Sanofi to co-commercialize the Covid Vaccine. Diane King Hall discusses this, as well as Novavax's 1Q earnings.
Other symbols: SNY
3 months ago - Schwab Network
Novavax stock soars on $1.2 billion Sanofi vaccine deal
Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brie...
Other symbols: SNY
3 months ago - Yahoo Finance
Novavax Stock Doubles on $1.2B Sanofi Deal for COVID-19, Flu Vaccines
Novavax (NVAX) shares more than doubled in intraday trading Friday after announcing a $1.2 billion deal to license its vaccine technology to French drugmaker Sanofi (SNY).
Other symbols: SNY
3 months ago - Investopedia
Novavax Shares Surge Over 140% After $1.4 Billion Covid Shot Deal With Sanofi
Shares for Novavax swelled by more than 140% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for ...
3 months ago - Forbes
Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps.
The two companies will also work on a shot that combines Covid-19 and flu vaccines.
Other symbols: SNY
3 months ago - Barrons
Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses
Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company's fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal wi...
Other symbols: SNY
3 months ago - Invezz
Novavax shares surge on new $1.4 billion deal with Sanofi
Novavax on Friday said it had struck a $1.4 billion deal with Sanofi to commercialize its existing COVID-19 vaccine and develop a new combined jab to inoculate against both the coronavirus and influen...
Other symbols: SNY
3 months ago - Market Watch